Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 70.49% is in line with its 5-year average of 67.07%, near the high end of its 5-year range (62.32%–70.70%).
0.51% above its 12-month average of 70.13%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 70.64%.
GROSS MARGIN
70.49%
GROSS MARGIN AVG TTM
70.13%
GROSS MARGIN AVG 3Y
67.44%
GROSS MARGIN AVG 5Y
67.07%
GROSS MARGIN AVG 10Y
64.66%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.51%
CURRENT VS 3Y AVG
+4.53%
CURRENT VS 5Y AVG
+5.10%
CURRENT VS 10Y AVG
+9.02%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+70.35%
vs the sector median at left
Establishment Labs Holdings Inc.
Market Cap
$1.92B
Gross Margin
70.49%
TTM Avg
70.13%
3Y Avg
67.44%
5Y Avg
67.07%
Market Cap
$1.94B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$1.89B
Gross Margin
78.67%
TTM Avg
83.63%
3Y Avg
79.97%
5Y Avg
53.31%
Market Cap
$1.96B
Gross Margin
82.92%
TTM Avg
-231.05%
3Y Avg
-241.31%
5Y Avg
-135.36%
Market Cap
$1.89B
Gross Margin
64.48%
TTM Avg
64.91%
3Y Avg
63.02%
5Y Avg
55.66%
Market Cap
$1.97B
Gross Margin
86.13%
TTM Avg
85.03%
3Y Avg
84.60%
5Y Avg
84.81%
Market Cap
$1.87B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Establishment Labs Holdings Inc. (ESTA) | $1.92B | 70.49% | 70.13% | 67.44% | 67.07% |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $1.94B | 0.00% | 0.00% | 0.00% | 0.00% |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.89B | 78.67% | 83.63% | 79.97% | 53.31% |
| AxoGen, Inc. (AXGN)vs › | $1.95B | 74.56% | 75.05% | 76.31% | 78.00% |
| Zymeworks Inc. (ZYME)vs › | $1.89B | 100.00% | 100.00% | 52.97% | -4.48% |
| Vir Biotechnology, Inc. (VIR)vs › | $1.96B | 82.92% | -231.05% | -241.31% | -135.36% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 64.48% | 64.91% | 63.02% | 55.66% |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.97B | 86.13% | 85.03% | 84.60% | 84.81% |
| Trevi Therapeutics, Inc. (TRVI)vs › | $1.87B | 0.00% | 0.00% | 0.00% | 0.00% |
| Fortrea Holdings Inc. (FTRE)vs › | $1.98B | 17.11% | 17.72% | 20.44% | 20.08% |
Gross Margin
70.5%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 70.64% |
| 2026-03-31 | 70.70% |
| 2025-12-31 | 70.46% |
| 2025-09-30 | 70.09% |
| 2025-06-30 | 68.76% |
| 2025-03-31 | 67.21% |
| 2024-12-31 | 68.50% |
| 2024-09-30 | 63.93% |
| 2024-06-30 | 65.59% |
| 2024-03-31 | 65.60% |
| 2023-12-31 | 65.22% |
| 2023-09-30 | 67.66% |
| 2023-06-30 | 62.32% |
| 2023-03-31 | 64.65% |
| 2022-12-31 | 64.28% |
| 2022-09-30 | 68.09% |
| 2022-06-30 | 66.65% |
| 2022-03-31 | 64.85% |
| 2021-12-31 | 68.60% |
| 2021-09-30 | 67.56% |
| 2021-06-30 | 67.10% |
| 2021-03-31 | 66.22% |
| 2020-12-31 | 54.31% |
| 2020-09-30 | 66.55% |
| 2020-06-30 | 69.07% |
| 2020-03-31 | 63.22% |
| 2019-12-31 | 67.46% |
| 2019-09-30 | 62.30% |
| 2019-06-30 | 60.01% |
| 2019-03-31 | 54.15% |
| 2018-12-31 | 60.21% |
| 2018-09-30 | 62.10% |
| 2018-06-30 | 59.94% |
| 2018-03-31 | 53.42% |
| 2017-12-31 | 55.57% |
| 2017-09-30 | 49.21% |
| 2017-06-30 | 47.81% |
| 2017-03-31 | 49.28% |
